Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m. ET in New York.

A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com.The webcast will be archived for at least 30 days following each presentation.

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

Design Therapeutics Inc (DSGN) PT Raised to $22 at Leerink Partners

Mon, 18 May 2026 10:28:58 -0400

Leerink Partners analyst Joseph Schwartz raised the price target on Design Therapeutics Inc (NASDAQ: DSGN) to $22.00 (from $18.00) while maintaining a Outperform rating.

Design Therapeutics Inc (DSGN) PT Raised to $20 at RBC Capital

Mon, 18 May 2026 09:35:17 -0400

RBC Capital analyst Leonid Timashev raised the price target on Design Therapeutics Inc (NASDAQ: DSGN) to $20.00 (from $14.00) while maintaining a Outperform rating.

The analyst comments "This morning based on early strong efficacy from RESTORE- FA, DSGN reported 4-week data and we had a chance to meet with the team to discuss their highly meaningful improvement in mFARS, USS and PROMIS at 1mg/kg IV dose at week 4. Moreover, the clinical improvements correlated with biomarker activity, with increase in FXN mRNA and protein in both muscle and blood, with no safety issues. While there are still some outstanding questions (small

Design Therapeutics Inc (DSGN) PT Raised to $20 at RBC Capital

Mon, 18 May 2026 09:35:17 -0400

RBC Capital analyst Leonid Timashev raised the price target on Design Therapeutics Inc (NASDAQ: DSGN) to $20.00 (from $14.00) while maintaining a Outperform rating.

Form 8-K Design Therapeutics, For: May 18

Mon, 18 May 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260518/26510099.html

Form 8-K Design Therapeutics, For: May 18

Mon, 18 May 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260518/26510099.html

Design Therapeutics reports positive trial data for Friedreich ataxia drug

Mon, 18 May 2026 07:01:56 -0400

Design Therapeutics Inc. (NASDAQ: DSGN) announced results from its Phase 1/2 RESTORE-FA trial showing that its experimental drug DT-216P2 produced clinical improvements and increased frataxin protein levels in patients with Friedreich ataxia after four weeks of treatment.

The trial included 16 patients who received weekly intravenous doses of DT-216P2 across four dose cohorts for four weeks. At the highest dose of 1 mpk, patients showed a mean improvement of 6.4 points on the modified Friedreich's Ataxia Rating Scale and 2.7 points on the Upright Stability Score from baseline.

The drug demonstrated dose-dependent increases in frataxin levels, with whole blood frataxin mRNA increasing

Design Therapeutics reports positive trial data for Friedreich ataxia drug

Mon, 18 May 2026 07:01:56 -0400

The drug demonstrated dose-dependent increases in frataxin levels, with whole blood frataxin mRNA increasing

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

Mon, 18 May 2026 07:00:00 -0400

DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing

DT-216P2 generally well-tolerated

Data support advancement toward registrational development